Providing a wide range of outlooks from bullish to bearish, 7 analysts have posted ratings on Align Tech ALGN in the last three months.
The table below summarizes their recent ratings, shedding light on changes in sentiment over the past 30 days and comparing them to previous months.
| Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
|---|---|---|---|---|---|
| Total ratings | 1 | 2 | 3 | 0 | 1 |
| Last 30 days | 0 | 0 | 1 | 0 | 0 |
| 1 million ago | 0 | 0 | 0 | 0 | 0 |
| 2 million ago | 1 | 1 | 1 | 0 | 0 |
| 3 million ago | 0 | 1 | 1 | 0 | 1 |
Analysts have set 12-month price targets for Align Tech, revealing an average target of $307.86, a high estimate of $355.00 and a low estimate of $225.00. This uptrend is evident, with the current average reflecting a 12.49% increase from the previous average price target of $273.67.
Analyst Ratings Analysis: A Detailed Analysis
Align Tech’s position among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent ratings, and adjustments to ratings and price targets.
| Analyst | Analytics company | Action taken | Assessment | Current price target | Previous price target |
|---|---|---|---|---|---|
| Kevin Caliendo | UBS | Raise | Neutral | $320.00 | $280.00 |
| Jonathan Block | Stifel | Raise | Acquire | $350.00 | $340.00 |
| Jason Bednar | Piper Sandler | Raise | Overweight | $355.00 | $335.00 |
| Michael Cherny | Leerink partner | Announce | Market performance | $310.00 | – |
| Nathan Rice | Goldman Sachs | Raise | Sell | $225.00 | $197.00 |
| Jason Bednar | Piper Sandler | Raise | Overweight | $335.00 | $290.00 |
| Kevin Caliendo | UBS | Raise | Neutral | $260.00 | $200.00 |
Key Insights:
- Action taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they “maintain,” “raise,” or “lower” their position, this indicates their reaction to recent developments related to Align Tech. This view provides a snapshot of analysts’ perspectives on the current state of the company.
- Assessment: Drilling down into the ratings, analysts assign qualitative values, from “Outperform” to “Underperform”. These ratings communicate expectations for Align Tech’s relative performance compared to the broader market.
- Price targets: Analysts measure the dynamics of price targets, providing estimates for the future value of Align Tech shares. This comparison reveals the trend in analyst expectations over time.
Analyzing these analyst ratings along with relevant financial metrics can provide a comprehensive view of Align Tech’s market position. Stay informed and make data-driven decisions with the assistance of our ratings table.
Stay updated on the ratings of Align Tech analysts.
Unraveling the story behind Align Tech
Align Technology is the leading manufacturer of clear aligners. Invisalign, its flagship product, was approved by the FDA in 1998 and has dominated ever since, controlling more than 90% of the market. Invisalign can treat approximately 90% of all cases of malocclusion (misaligned teeth), and there are over 230,000 dentists and orthodontists trained in Invisalign. In 2022, Invisalign treated more than 2 million cases, or approximately 10% of all orthodontic cases for the year, and has treated more than 14 million patients since its launch. Align also sells intraoral scanners under the iTero brand, which take digital impressions of patients’ teeth and explain treatment plans. Over 85% of Invisalign cases are sent via digital scans, and iTero scans make up over half of these scans.
Align Tech: financial performance analyzed
Market Cap Highlights: Above the industry average, the company’s market capitalization represents a significant scale, indicating strong confidence and prominence in the market.
Revenue growth: Align Tech has shown positive results in 3 months. As of December 31, 2023, the company achieved a solid revenue growth rate of approximately 6.12%. This indicates a notable increase in the company’s profits. Compared to its industry peers, the company lags behind with a growth rate below average among healthcare industry peers.
Net margin: Align Tech’s financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a significant net margin of 12.96%, the company has strong profitability and effective cost management.
Return on equity (ROE): Align Tech’s ROE exceeds industry standards, highlighting the company’s exceptional financial performance. With an impressive 3.34% ROE, the company actually uses shareholders’ equity.
Return on Assets (ROA): The company’s ROA is exceptional and exceeds industry averages. With an impressive ROA of 2.0%, the company demonstrates effective use of resources.
Debt Management: Align Tech’s debt-to-equity ratio is lower than the industry average. With a ratio of 0.03the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Explanation of the meaning of analyst ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually over the next five years, and how risky or predictable the company’s revenue streams will be.
Analysts participate in conference calls and company meetings, research companies’ financial statements, and communicate with insiders to publish their stock ratings. Analysts typically rate each stock once a quarter or whenever the company has a major update.
In addition to their ratings, some analysts extend their insights by offering forecasts for key metrics such as earnings, revenue and growth estimates. This additional information provides further guidance for traders. It is critical to recognize that despite their specialization, analysts are human and can only provide predictions based on their beliefs.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.